AstraZeneca Drops Targacept's Failed ADHD Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
After receiving disappointing news about one of its Phase 2 NNR drugs, Targacept waits to hear from its partner, AZ
You may also be interested in...
Deals Of The Week Untangles The String Of Pearls
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute
The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.
Targacept, AstraZeneca Face Another Failure With NNR Class
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.